Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of BEMA Buprenorphine NX for Induction in Opioid Dependence
NCT02516436Phase 3Withdrawn
- Sponsor
- BioDelivery Sciences International
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of buprenorphine + naloxone in opioid use disorder (OUD) (2 arms), sponsored by BioDelivery Sciences International. Primary endpoint: Change from Baseline in Clinical Opiate Withdrawal Scale (COWS) total score at 12 hours. Status: withdrawn.
02
Drugs
buprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02516436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516436.